C. Blank

Oncology · 2004–2021

A researcher in the Science corpus: 20 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Oncology — 251 citations into it
• Immunology — 162 citations into it

Whom C. Blank trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Taku Okazaki
2. M. Dudley
3. G. Freeman
4. B. Carreno
5. James P. Allison
6. Arlene H. Sharpe

Who trusts C. Blank overall

1. D. Pardoll
2. Antoni Ribas
3. S. Topalian
4. Gabriel A. Rabinovich
5. C. Robert
6. S. Patel

Papers from C. Blank's perspective

Ordered by how strongly the researchers C. Blank trusts endorse each paper. Same corpus, a different order for every researcher.

1. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. (Science)
2. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation (Journal of Experimental Medicine)
3. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade (Proceedings of the National Academy of Sciences of the United States of America)
4. Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity (Nature Medicine)
5. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 (Journal of Immunology)
6. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes (Science)
7. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma (Proceedings of the National Academy of Sciences of the United States of America)
8. PD-L2 is a second ligand for PD-1 and inhibits T cell activation (Nature Immunology)
9. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion (Nature Medicine)
10. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome (Science)

Their papers

• The human tumor microbiome is composed of tumor type-specific intracellular bacteria (2020) — 2,022 citations
• Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma (2014) — 815 citations
• Pembrolizumab versus Ipilimumab in Advanced Melanoma. (2015) — 5,305 citations
• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. (2012) — 2,840 citations
• Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. (2019) — 933 citations
• Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma (2021)
• B cells and tertiary lymphoid structures promote immunotherapy response (2020) — 2,250 citations
• Integrative molecular and clinical modeling of clinical outcomes to PD-1 blockade in metastatic melanoma patients (2019) — 824 citations
• Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial (2019) — 793 citations
• Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (2018) — 786 citations
• Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (2018) — 1,561 citations
• Dysfunctional CD8+ T cells form a proliferative, dynamically regulated compartment within human melanoma (2018) — 1,027 citations
• Identification of CMTM6 and CMTM4 as PD-L1 protein regulators (2017) — 631 citations
• Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). (2017) — 1,099 citations
• LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. (2016) — 1,711 citations
• The “cancer immunogram” (2016) — 596 citations
• Genomic correlates of response to CTLA-4 blockade in metastatic melanoma (2015) — 2,605 citations
• MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. (2013) — 625 citations
• Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy (2005) — 621 citations
• PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells (2004) — 757 citations